Articles written by Dmitry Reichart - Benzinga

Victories And failures Of Roche, Bristol Myers, and Merck And Why It's Worth Investing In Immunotherapy Now

The discovery of immune checkpoint proteins was a breakthrough in cancer immunotherapy. Today, Merck, Roche, and Bristol Myers are leading the immuno-oncology race, with Merck's Keytruda dominating. Bristol Myers's Opdivo is one step behind, while Roche is still looking for its niches after several failures.

Investment In The Pharmaceutical Market During The Recession: New Reality Of Market

The pharmaceutical market is least affected by negative events in the world economy Specialized strategies which take into account peculiarities of different markets are efficient The actual return in pharma has already reached 24.85% and a YTD return is currently 7.35%.